In patients with active rheumatoid arthritis despite therapy with DMARDS, 
treatment with a spleen tyrosine kinase inhibitor has achieved similar response 
rates to those achieved in clinical trials of other drugs, including biologic 
agents. Where might these agents fit in the current armamentarium against this 
disease?